It has been known for more than 80 years that cancer cells alter their use of metabolic pathways as a means for enhanced proliferation and survival [1, 2] . In fact, changes in intracellular metabolism are now considered to be one of the hallmarks of oncogenic transformation, along with genomic instability, hyperproliferation, evasion of apoptosis, immortalization, metastasis induction, and activation of angiogenesis [3] . Such metabolic adjustments are essential for tumor cells to acquire sufficient sources of energy and to generate the biosynthetic building blocks required for cell growth and division. A paper recently published in Current Biology by Cui et al. [4] provides novel links between changes in metabolism and the role of the well-known tumor suppressor Rb.
The best-characterized metabolic change associated with tumors, known as the Warburg effect, refers to the strong preference of many cancer cells for glycolysis over oxidative phosphorylation [1, 2] . Although less efficient in terms of producing ATP, glycolysis has the advantage of generating macromolecular precursors that are required for growth as well as antioxidants that are used to neutralize reactive oxygen species created during rapid proliferation. To offset potential deficits in energy production, cancer cells typically increase their uptake of extracellular glucose. In addition, cancer cells can display enhanced glutamine uptake and processing and exhibit increased lipid, protein, and nucleotide biosynthesis [1, 2] . Also, many solid tumor cells undergo adaptive physiological changes triggered by hypoxia and acidosis [5] .
Only recently have direct connections been established between the altered metabolism of tumor cells and the genetic changes associated with cancer progression. Oncogenes and tumor suppressors that have been implicated in metabolic transformation include several key players in the phosphatidylinositol 3-kinase (PI3K) pathway, including PTEN, AKT, and mTOR, mutations in which promote glycolysis and glucose uptake [1] [2] [3] 6] . In addition, the transcription factor and tumor suppressor p53 regulates metabolism by several independent mechanisms, including activation of PTEN, and loss of p53 is thought to contribute significantly to the glycolytic phenotype [1, 2, 6] . Finally, one of the earliest identified oncogenes, MYC, stimulates glutamine uptake and metabolism and promotes glucose internalization and glycolysis via hypoxia-inducible factor 1 (HIF1), a target of mTOR [1, 6] .
One of the most intensively studied tumor suppressors is the retinoblastoma protein pRb [7, 8] , which is functionally inactivated in most human cancers and has been implicated in many cellular and developmental processes that contribute to its functions as a tumor suppressor [3, 9] . This includes the well-established role of pRb in repressing cell-cycle progression but also encompasses functions relevant to genome stability, differentiation, quiescence, senescence, invasion, and angiogenesis. Notably, studies in non-mammalian systems, including Caenorhabditis elegans, have implicated pRb orthologs in biological processes that correlate well with reported roles of pRb in mammalian tumor suppression. In C. elegans, for example, the pRb ortholog, LIN-35, regulates progression through the cell cycle, differentiation, apoptosis, morphogenesis, and growth factor expression [10] . The recent paper by Cui et al. [4] now demonstrates a novel function for LIN-35/pRb in metabolic control, which may also be relevant to its role in humans as a tumor suppressor.
In their natural environment, C. elegans frequently encounter starvation conditions, which require compensatory changes to cellular metabolism and developmental programs. One key decision point occurs after hatching: worms in the first larval stage (L1) that are hatched in the absence of food undergo a developmental arrest referred to as the L1 diapause. The survival of starved L1 worms requires the activity of a conserved insulin-IGF-1 signaling (IIS) pathway, which indicates that the regulation of metabolism is conserved between C. elegans and higher eukaryotes [11] . Cui et al. [4] showed that the survival of starved L1 worms also depended on LIN-35/pRb because lin-35/Rb loss-of-function mutants were markedly sensitive to nutrient deprivation.
To gain insights into the mechanistic basis for LIN-35/pRb-mediated diapause survival, Cui et al. [4] performed a microarray analysis to compare wild-type and lin-35/Rb mutants. Rather surprisingly, the spectrum of genes that was regulated by LIN-35/pRb differed quite dramatically between fed and starved L1 worms, suggesting that there are categorically distinct functions for LIN-35/pRb under different growth conditions [12] . These findings indicate that, although LIN-35/pRb does not directly regulate most IIS pathway components, LIN-35/pRb and the IIS pathway co-regulate the expression of 58 genes in a manner that is largely antagonistic. However, genetic and microarray data suggest that LIN-35/pRb also promotes diapause survival through several mechanisms that are independent of the IIS pathway. This latter contention is supported by phenotypic analysis showing that glucose supplementation dramatically improved the survival of starved IIS pathway mutants but had only weak effects on lin-35/Rb mutants.
With respect to other relevant metabolic targets, LIN-35/pRb repressed the expression of many genes induced by toxins, pathogens, and oxidative stress. However, LIN-35/pRb also positively regulated glutathione transferase genes that are critical for redox homeostasis, and lin-35/Rb mutants were hypersensitive to oxidative stress during L1 diapause. In addition, LIN-35/pRb controls the expression of many genes that encode mitochondrial respiratory chain components, which may be important mediators of the response to starvation. More globally, under conditions of nutrient deprivation, LIN-35/pRb is required for maintaining a transcriptional profile that is consistent with starvation. In the absence of LIN-35/pRb, starved animals displayed expression profiles that were more reminiscent of well-fed worms, which (perhaps not surprisingly) was deleterious for survival.
Interestingly, the role of LIN-35/pRb in L1 diapause survival is dependent to a large extent on the expression of LIN-35/pRb in neurons and, to a lesser degree, in the intestine. In contrast, expression of LIN-35/pRb in one of the major tissues of the worm, the hypodermis (epidermis), was not essential for diapause survival. The data did, however, suggest that tissues other than neurons and the intestine must also contribute to the role of LIN-35/pRb in the starvation response. Taken together, their findings indicate that LIN-35/pRb normally promotes diapause survival through a number of distinct metabolic pathways and in multiple tissue types.
One limitation of this current study is the reliance on microarray data in accounting for the mechanistic role of LIN-35/pRb in regulating the starvation response. Given that LIN-35/pRb differentially regulates more than 1,200 genes in starved L1 animals, it would, however, be difficult to functionally assess the contribution of individual genes or gene classes in this process. An important open question is whether or not LIN-35/pRb directly regulates genes implicated in the starvation response. One hint that at least some of the targets are direct is the observation that worms that had reduced function in the C. elegans E2F ortholog, efl-1, were also somewhat hypersensitive to L1 starvation. E2F transcription factors are conserved binding partners of pRb family members and together form the core of several multisubunit transcriptional repressor complexes [7] . In addition, a comparison of LIN-35/pRb transcriptional targets in starved L1s with experimentally verified LIN-35/pRb genomic binding sites showed a significant overlap, suggesting that regulation by LIN-35/pRb may in some cases be direct [13] .
Admittedly, the role of LIN-35/pRb in the starvation response could be a unique feature of C. elegans. A paper by Nicolay et al. [14] published earlier this year does, however, suggest that a function for pRb in the starvation response may be conserved. Drosophila cells that are mutant for rbf1, one of the two Rb homologs in flies, are hypersensitive to fasting conditions, as are intact fly larvae in which rbf1 activity has been partially inactivated. Furthermore, RBF1 regulates genes involved in glutamine and nucleotide metabolism, a finding supported by metabolic profiling of fly larvae depleted for rbf1. The increased demand for glutamine in rbf1-depleted larvae is responsible for their hypersensitivity to fasting conditions, and rbf1-depleted tissues are also vulnerable to oxidative stress. In addition, Nicolay et al. [14] demonstrated that in multiple human cancer cell lines loss of Rb altered the metabolism of glutamine, leading to alterations in energy production, redox balance, and nucleotide pools.
Additional recent reports have also implicated pRb family members in the control of metabolism. The simultaneous loss of both rbf1 and gig/TSC2, a negative regulator of TOR signaling, results in the induction of cell death in fly tissues and leads to a synergistic increase in oxidative stress in mammalian cells [15] . Moreover, pRb, along with its binding partner E2F1, has also been implicated in the control of oxidative metabolism in fat tissue, and targeted deletion of Rb and associated factors in mice can lead to severe metabolic alterations [2, [16] [17] [18] [19] . Still other reports have linked the pRb pathway to lipid and oxidative metabolism and to mitochondrial biogenesis [16, 19, 20] . Finally, pRb is regulated in part through phosphorylation by AMP kinase, a key regulator of cellular energy homeostasis [19] .
Although the relative impact of the pRb pathway on cancer cell metabolism still remains to be determined, the findings by Cui et al. [4] , together with other studies, are starting to build a compelling case (Figure 1) . Nevertheless, the effects of pRb family members on metabolism appear to be quite complex and, in some instances, contradictory. Interestingly, loss of Rb often appears to render cells less fit to cope with the metabolic requirements and physiological stresses that are encountered by tumor cells. This may point to therapies based on the metabolic vulnerabilities of Rb-deficient tumors but also suggests that cancer cells may be capable of evolving the means to counter these deficiencies.
